Palatin Technologies (NYSEAMERICAN:PTN) Stock Price Down 9.6% – Here’s Why

Palatin Technologies (NYSEAMERICAN:PTN)’s share price traded down 9.6% during mid-day trading on Monday . The company traded as low as $10.05 and last traded at $10.34. 36,903 shares were traded during trading, an increase of 81% from the average daily volume of 20,444 shares. The stock had previously closed at $11.44.

Palatin Technologies Trading Down 9.6%

The firm’s fifty day moving average is $15.76 and its 200-day moving average is $17.86.

Palatin Technologies (NYSEAMERICAN:PTN) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.87. The firm had revenue of $3.92 million during the quarter, compared to analyst estimates of $1.28 million.

Institutional Investors Weigh In On Palatin Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bleichroeder LP bought a new position in Palatin Technologies in the 4th quarter valued at $120,000. Jane Street Group LLC acquired a new stake in shares of Palatin Technologies in the fourth quarter valued at $166,000. Millennium Management LLC acquired a new stake in shares of Palatin Technologies in the fourth quarter valued at $206,000. Geode Capital Management LLC acquired a new position in Palatin Technologies during the 4th quarter worth about $272,000. Finally, Superstring Capital Management LP acquired a new stake in Palatin Technologies in the 4th quarter valued at about $522,000. 11.50% of the stock is owned by institutional investors and hedge funds.

Palatin Technologies Company Profile

Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.